

Anti-Inflammatory Reliever (AIR) Therapy

BUDESONIDE + FORMOTEROL Symbicort®	DUO RESP SPIROMAX®
	
100/6 200/6 Turbuhaler®	200/6 Dry powder inhaler

Short-Acting Beta2 Agonists (SABA)

SALBUTAMOL SalAir®	VENTOLIN®
	
100 mcg Aerosol inhaler	250 mcg Turbuhaler®

Short-Acting Muscarinic Antagonists (SAMA)

IPRATROPIUM Atrovent®

20 mcg Aerosol inhaler

Combination SABA + SAMA

SALBUTAMOL + IPRATROPIUM Duolin HFA®

100 mcg/20 mcg Aerosol inhaler

RELIEVERS

Inhaled Corticosteroids (ICS)

FLUTICASONE propionate Flixotide®

50 mcg 125 mcg 250 mcg Aerosol inhaler
50 mcg 100 mcg 250 mcg Accuhaler®

BUDESONIDE Pulmicort®

100 mcg 200 mcg 400 mcg Turbuhaler®

BECLOMETHASONE dipropionate Beclazone®	Qvar® (ultrafine particle)
	
50 mcg 100 mcg 250 mcg Aerosol inhalers	50 mcg 100 mcg Aerosol inhalers

Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

BUDESONIDE + FORMOTEROL Symbicort®	DUO RESP SPIROMAX®	VANNAIR®
		
100/6 200/6 400/12* Turbuhaler®	200/6 400/12* Dry powder inhaler	100/6 200/6 Aerosol inhaler

*Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day

Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.

RELIEVER + PREVENTER

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

FLUTICASONE propionate + SALMETEROL Seretide®

50/25 125/25 250/25 Aerosol inhaler

*100/50 and 250/50 accuhaler only funded

if no more than 2 doses per day

FLUTICASONE furoate + VILANTEROL Breo Ellipta®

100/25 200/25 Dry powder inhaler

CONTROLLER + PREVENTER

Long-Acting Beta2 Agonists (LABA)

SALMETEROL Serevent®	FORMOTEROL (eformoterol) Oxis®	INDACATEROL Onbrez Breezhaler®
		

Long-Acting Muscarinic Antagonists (LAMA)

TIOTROPIUM Spiriva®	SPIRIVA RESPIMAT®	UMECLIDINIUM Incruse Ellipta®	GLCOPYRRONIUM Seebri Breezhaler®
			

Funded by endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription). Not subsidised if patient is also receiving treatment with another subsidised LAMA.


Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA)

TIOTROPIUM + OLODATEROL Spiolto Respimat®	UMECLIDINIUM + VILANTEROL Anoro Ellipta®	GLCOPYRRONIUM + INDACATEROL Ultibro® Breezhaler®
		

Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.

LONG-ACTING SYMPTOM CONTROLLERS (FOR COPD)

Combination Inhaled Corticosteroids (ICS) + Long-Acting Muscarinic Antagonist (LAMA) + Long-Acting Beta2 Agonist (LABA)

FLUTICASONE furoate + UMECLIDINIUM + VILANTEROL Trelegy Ellipta®	BUDESONIDE + GLCOPYRRONIUM + FORMOTEROL Breztri Aerosphere®
	

Funded via Special Authority: ICS + LAMA + LABA 'triple therapy' inhaler is subsidised only for patients with a diagnosis of COPD confirmed by spirometry, or spirometry has been attempted and technically acceptable results are not possible and the patient is currently on an ICS/LABA or a LAMA/LABA, and meets the following clinical criteria:

- Patient has a COPD Assessment Test (CAT) score greater than 10, or
- Patient has had 2 or more exacerbations in the previous 12 months, or
- Patient has had one exacerbation requiring hospitalisation in the previous 12 months, or
- Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months or the patient is currently receiving multiple inhaler triple therapy (ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to starting multiple inhaler triple therapy.

Spacers are available free to those who need them on a Practitioners Supply Order (PSO). Contact Manatū Hauora Ministry of Health for an order form on 0800 353 2425.

Everyone should have an action plan. Find a range of management plans at asthmafoundation.org.nz

 Funded

 Not funded

 Partially funded

 Funded by endorsement

 Funded by Special Authority

 Low carbon footprint¹

 High carbon footprint¹

Funding information updated as of 1 June 2025.

Visit www.pharmac.govt.nz

DOWNLOAD AT:

asthmafoundation.org.nz